secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2026-11-10T21:46:21+00:00
Accession:  0001628280-26-072809
Event type: earnings
Sentiment:  neutral
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Azenta FY26 revenue $622M, up 5%; GAAP EPS -$3.50 on $149M impairment; FY27 revenue guided $648-660M
--------------------------------------------------------------------------------

- Q4 revenue $167M, +5% YoY (+2% organic); Sample Management Solutions $94M (+9%), Multiomics $73M flat; adjusted diluted EPS $0.28 vs $0.21 a year ago.
- FY26 GAAP operating loss $174.7M and continuing-ops diluted EPS of -$3.50, including a $149M non-cash goodwill impairment; adjusted EPS $0.48 vs $0.51.
- FY27 outlook: revenue $648-660M, organic growth 3-5%, adjusted EBITDA margin up 200-250 bps including 100 bps dilution from Elegen and SynPlexity; FCF up ~25%.
- Acquired SynPlexity Oct 28 for $15M cash ($2.5M holdback) plus up to $10M contingent; Elegen license carries $23M fixed payments and a $25M perpetual conversion option.
- B Medical Systems sold July 1, 2026, with the $35M vendor loan repaid Sept 3; FY26 repurchases totaled 4.4M shares for $118.2M, $131.8M left on the $250M program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000162828026072809/0001628280-26-072809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000162828026072809/azta-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-072809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer